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Primary biliary cirrhosis (PBC) is characterized by antimitochondrial antibodies (AMAs), di-
rected to the E2 component of the pyruvate dehydrogenase complex (PDC-E2). Notwithstand-
ing the presence ofmitochondria in virtually all nucleated cells, the destruction in PBC is limited
to small intrahepatic bile ducts. The reasons for this tissue speciﬁcity remain unknown, although
biliary epithelial cells (BECs) uniquely preserve the PDC-E2 epitope following apoptosis. Nota-
bly, PBC recurs in an allogeneic transplanted liver, suggesting generic rather than host PBC–
speciﬁc susceptibility of BEC.We used cultured human intrahepatic BECs (HIBECs) and other
well-characterized cell lines, including, HeLa, CaCo-2 cells, and nontransformed human kera-
tinocytes and bronchial epithelial cells, to determine the integrity and speciﬁc localization of
PDC-E2 during induced apoptosis. All cell lines, both before and after apoptosis, were tested
with sera frompatients with PBC (n 30), other autoimmune liver and rheumatic diseases (n
20), and healthy individuals (n  20) as well as with a mouse monoclonal antibody against
PDC-E2 and AMA with an immunoglobulin A isotype. PDC-E2 was found to localize unmod-
iﬁed within apoptotic blebs of HIBECs, but not within blebs of various other cell lineages
studied. The fact that AMA-containing sera reacted with PDC-E2 on apoptotic BECs without a
requirement for permeabilization suggests that the autoantigen is accessible to the immune
systemduring apoptosis.Conclusion:Our data indicate that the tissue (cholangiocyte) speciﬁcity
of the autoimmune injury in PBC is a consequence of the unique characteristics of HIBECs
during apoptosis and can be explained by exposure to the immune system of intact immunore-
active PDC-E2 within apoptotic blebs. (HEPATOLOGY 2009;49:871-879.)
Apoptotic cells are normally efﬁciently cleared afterengulfment by “professional” phagocytes fol-lowed by an anti-inﬂammatory response.1,2 When
such uptake is impaired, cell lysis can release intracellular
components that are a potential source of autoantigenic
stimulation3-6 and autoimmunity onset.7-9 The presence
of intact autoantigens within apoptotic blebs,10 their par-
ticipation in the processes involved in autoantigen presen-
tation,11 and the activation of innate immunity through
macrophage cytokine secretion in concert12 are likely
links between apoptosis and autoimmunity. Of relevance
to the autoimmune liver disease primary biliary cirrhosis
(PBC),Odin and colleagues demonstrated that, following
apoptosis of biliary epithelial cells (BECs), the autoanti-
genic E2 subunit of the pyruvate dehydrogenase complex
(PDC-E2) remains immunologically intact and still rec-
ognizable as such by antimitochondrial autoantibodies
(AMAs).13 It is reasoned that absence of glutathiolation13
may contribute to this unique feature of the BEC.
We reasoned that immune-mediated BEC destruction
would be accentuated if PDC-E2 were preserved in blebs
during apoptosis. Indeed, this could lead to impaired
clearance of such apoptotic cells, thus provoking an in-
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nate immune response and even the autoimmune destruc-
tion of bile ducts. This scenario would help explain the
recurrence of PBC following orthotopic liver transplanta-
tion,14 as well as the therapeutic failure of immunosup-
pressive agents.15 We report here the cellular topology of
PDC-E2 during apoptosis of cultured human intrahe-
patic BECs (HIBECs) and other non-BEC cells. Our
ﬁndings demonstrate that PDC-E2 is localized intact
within blebs of apoptotic HIBECs and is thereby accessi-
ble to the immune system. We hypothesize that the
unique HIBEC apoptotic features allow the exposure of a
potent intracellular autoantigen to the PBC-associated
multilineage autoimmune response that leads to the tis-
sue-speciﬁc autoimmune injury.
Patients and Methods
Human Sera and Antibodies. After informed con-
sent was given, serum samples were obtained from pa-
tients diagnosed with PBC (n  30), systemic lupus
erythematosus (SLE; n  5), autoimmune hepatitis
(AIH, n  5), primary sclerosing cholangitis (PSC, n 
5), chronic hepatitis C (CHC, n  5), and healthy indi-
viduals (n 10). PBC sera included 20 randomly chosen
AMA-positive cases and 10 well-deﬁned patients who
were AMA-negative; thus, the proportion of AMA-nega-
tive sera utilized in this study is signiﬁcantly higher than
the normally expected frequency because these were spe-
ciﬁcally sought for this study. The diagnosis of all cases
was based on established criteria for PBC,16 SLE,17
AIH,18 PSC,19 and by detection of serum hepatitis C virus
(HCV) RNA for CHC by polymerase chain reaction. As
expected, 90% (27 of 30) of PBC cases were women and
70% were taking ursodeoxycholic acid as the sole treat-
ment at the time of enrollment. The mean age was 63
10 years, and 17 of 30 patients had advanced PBC (his-
tological stages III-IV). These clinical features did not
differ between patients with AMA-positive or AMA-neg-
ative PBC (data not shown).
Antibody Reagents. Serum anti–PDC-E2 antibodies
were tested using our well-deﬁned assays with recombi-
nant antigens, as explained below.20-22 We also utilized a
previously described mouse monoclonal antibody (mAb)
against PDC-E2, clone 2H-4C8.23 Secondary antibodies
Cy3-labeled anti–human-immunoglobulin G (IgG), an-
ti–human-IgA, and anti–mouse-IgG were purchased
from Jackson ImmunoResearch (West Grove, PA). Nor-
mal mouse IgG was obtained from Invitrogen (Carlsbad,
CA) and ﬂuorescein isothiocyanate (FITC)-labeled an-
nexin-V was obtained from BD Pharmingen (San Jose,
CA). Monoclonal anti–human caspase-3 antibody was
purchased fromR&DSystems (Minneapolis, MN). Neg-
ative controls were used throughout and included sera
from healthy individuals. Additionally, we puriﬁed IgA-
AMA from a patient diagnosed with PBC and a mono-
clonal gammopathy with high levels of IgA-AMA using
Jacalin-agarose beads (Pierce, Rockford, IL) following the
manufacturer’s instructions. Serum IgA from a healthy
subject was used as a control.
Detection of AMA. An established optimal amount
(16 g) of puriﬁed recombinant PDC-E2 was loaded
onto a 10% mini protein gel (Bio-Rad Laboratories, Her-
cules, CA), fractionated at 170 V for 1 hour, and trans-
ferred overnight onto nitrocellulose membranes that were
then cut into strips. AMA detection was performed as
described.24 The samples to be analyzed included sera
from patients with PBC at an optimal dilution of 1:2000,
monoclonal AMA (104 dilution), pooled AMA of IgA
isotype (dilution 1:2000), and control IgA (1:2000).
Blots were exposed on photographic membranes and im-
ages were digitized with a FluorTech 8900 gel doc system
(Alpha Innotech, San Leandro, CA) equipped with a
chemiluminescent ﬁlter. The absence of AMAwas further
conﬁrmed in the sera of the patients who were AMA-
negative, using our standardized enzyme-linked immu-
nosorbent assay (ELISA) and pMIT-3 antigens.25
Cell Lines and Culture Conditions. The cells stud-
ied were cultured HIBECs, two human epithelial non-
transformed primary cell cultures (human keratinocytes
and bronchial epithelial cells [BrEpCs]) purchased from
ScienCell (San Diego, CA) and two human tumor-de-
rived laboratory cell lines, HeLa cells and CaCo-2 cells
purchased from American Type Culture Collection (Ma-
nassas, VA). HIBECs were cultured in sterile medium
supplemented with 2% fetal bovine serum (FBS), epithe-
lial cell growth supplement (ScienCell, San Diego, CA),
and 1% penicillin in cell culture ﬂasks coated with poly-
L-lysine (Sigma-Aldrich, St Louis, MO). The other two
epithelial cells were cultured under the same conditions in
absence of FBS, as recommended by the manufacturer.
HeLa and CaCo-2 cells were cultured using low glucose
Dulbecco’s modiﬁed Eagle medium, supplemented with
10% FBS for HeLa cells and 20% for CaCo-2 cells, gen-
tamicin (6 g/mL), sodium pyruvate (110 mg/L), and
L-glutamine (2 mM). Cells were cultured at 37°C in a
humidiﬁed 5% CO2 incubator.
HIBECs were isolated from human liver tissue by the
supplier and cryopreserved immediately after puriﬁca-
tion. This primary cell culture was characterized by an
immunoﬂuorescence method with antibodies to cytoker-
atin 18, cytokeratin 19, and vimentin which stained more
than 90% of the cells. All experiments on HIBECs were
performed between cell passage 2 and 5.
Induction of Apoptosis. We used biliary salts (BS) to
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induce apoptosis.26 To establish optimal conditions for
the induction of apoptosis, we incubated all the cells types
at 37°C for 1, 2, 3, and 4 hours using different concen-
trations (100M, 500M, 1mM, and 2mM) of sodium
glycochenodeoxycholate (GCDC; Sigma-Aldrich) added
to normal culture medium, and in absence of serum and
growth factors.26 BS failed to induce any apoptotic effect
in HeLa and Caco-2 cells so, in these transformed cell
lines, apoptosis induction was performed by ultraviolet B
light (UVB) irradiation, at 1650 J/m2 for HeLa cells and
2200 J/m2 for CaCo-2 cells, followed by incubation in
fresh media for 8 (HeLa) or 16 (CaCo-2) hours.13 Apo-
ptosis was also induced in HIBECs by UVB irradiation
(1650 J/m2) followed by incubation in fresh medium for
6 hours.
Quantiﬁcation of Apoptosis by Flow Cytometry.
The cells to be analyzed for apoptosis were suspended in
200 L of buffer containing 10 mM Hepes/NaOH (pH
7.4), 140 mM NaCl, and 2.5 mM CaCl2. A total of 1
106 cells were stained for 15minutes at room temperature
in the dark with FITC-labeled annexin-V and with pro-
pidium iodide (BD Pharmingen, San Jose, CA) to dis-
criminate apoptotic from necrotic cells. The samples were
immediately analyzed by ﬂow cytometry, and at least
10,000 events were counted. Stained cells were assessed
on a ﬂuorescence-activated cell sorting (FACS) FACScan
ﬂow cytometer (BD Immunocytometry Systems, San
Jose, CA) upgraded by Cytec Development (Fremont,
CA). Acquired data were analyzed with CellQuest Pro
(BD Immunocytometry Systems) and FlowJo (Tree Star
Inc., Ashland, OR) software packages.
Immunostaining and Confocal Microscopy. Cells
were washed twice with phosphate-buffered saline (PBS)
and incubated with FITC-labeled annexin-V at 1:10 di-
lution for 15 minutes at room temperature (RT) in the
dark. The samples were then ﬁxed in 3.7% formaldehyde
(5 minutes at RT), permeabilized with 0.2% Triton
X-100 (5 minutes at RT) and blocked for 30 minutes at
RT with 1 Universal blocking solution (Bio-Genex).
Immunoﬂuorecence staining was performed with human
sera diluted 1:40 or monoclonal antibody diluted 1:80
(overnight, 4°C), followed by Cy3-labeled secondary an-
tibody diluted 1:500 for 1 hour at RT. The cells were
costained with 4,6-diamidino-2-phenylindole (DAPI;
Invitrogen, Carlsbad, CA) to visualize nuclear degenera-
tion. All samples were stained when at 80% conﬂuence;
samples with less than 100 cells were excluded. Identical
settings were used for all samples. Controls consisting of
incubation of cells with developing secondary antibody
alone did not demonstrate any detectable staining under
the same conditions.
Staining of nonapoptotic and apoptotic HIBECs was
also performed in the absence of membrane-perforating
agent. The same protocol previously described was fol-
lowed but Triton X-100 was omitted. Immunoﬂuores-
cence-labeled samples were examined using a Pascal Zeiss
confocal laser scanning microscope with a 100 oil-im-
mersion objective.
Isolation and Immunoblot Analysis of Apoptotic
Bodies. After induction of apoptosis, subcellular frag-
ments were isolated by ﬁltration and ultracentrifugation
as described elsewhere.10 Brieﬂy, the cell culture superna-
tant ﬂuid was collected after apoptosis induction. Two
additional centrifugation steps (500g for 5 minutes) were
performed in order to remove the remaining cells. The
supernatant ﬂuid was then passed through a 1.2m non-
pyrogenic, hydrophilic syringe ﬁlter. After centrifugation
at 100,000g for 30 minutes, the pellet containing apopto-
tic bodies (AB) was resuspended in lysis buffer containing
a protease inhibitor cocktail (Roche Diagnostics, India-
napolis, IN). Lysis was performed for 30 minutes on ice.
Protein content of the samples was determined by the
BCA (bicinconic acid) assay using a Nanodrop ND-1000
ultraviolet-visible Spectrophotometer (NanoDrop Tech-
nologies, Wilmington, DE). Each sample (20 g) was
diluted in loading buffer and subjected to standard so-
dium dodecyl sulfate polyacrylamide gel electrophoresis.
After transfer to polyvinylidene ﬂuoride membranes,
PDC-E2 was detected using the monoclonal antibody
previously described (clone 2H-4C8),23 and AMA-posi-
tive sera with two different AMA isotypes.
Results
Apoptosis in HIBECs. Apoptosis rates were evaluated
in all cell lines by FACS (annexin V and propidium iodide
double staining) and immunoﬂuorescence. Apoptotic
cells were identiﬁed with confocal microscopy by mor-
phological criteria: high nuclear density, chromatin con-
densation, and nuclear fragmentation revealed with
DAPI, and characteristic blebbing of the cell membrane
revealed with annexin-V; on the basis of these character-
istics, an apoptotic index was established as: (DAPI-apo-
ptotic nuclei/total nuclei) 100.
Bile salts (BS) accumulating in the human liver in the
course of cholestatic conditions trigger liver injury and
subsequent ﬁbrosis, and it has been demonstrated that a
constituent of the hydrophobic BS, glycochenodeoxy-
cholate (GCDC), induces apoptosis of hepatocytes start-
ing at a concentration of 50 M.27 GCDC has also an
apoptotic effect in cholangiocytes.26 The use of 1 mM
GCDC in the absence of serum, or growth factors, in-
duced apoptosis in 39% of HIBECs, whereas UVB irra-
HEPATOLOGY, Vol. 49, No. 3, 2009 LLEO ET AL. 873
diation (1650 J/m2 followed by incubation in fresh
medium at 37°C for 6 hours) induced apoptosis in just
11% of HIBECs; moreover, in our experience, a higher
level of double-positive propidium iodide/annexinV cells,
most probably referable to necrotic cells, was generated
following UVB irradiation compared to BS in HIBECs
(Fig. 1A). Under both sets of conditions, membrane bleb-
bing and apoptotic fragments were observed in HIBECs
using confocal microscopy (Fig. 1C). The levels of apo-
ptosis in HeLa and CaCo-2 cells after UVB irradiation
were similar to those reported in the literature, i.e., 45%,
and 60%, respectively.28 GCDC induced apoptosis in
49% of BrEpCs and 52% of keratinocytes. On the other
hand, no substantial level of apoptosis was observed in
HeLa and CaCo-2 cells after incubation with BS.
In conclusion, GCDC at 1 mM in serum-free medium
was chosen to induce apoptosis in HIBECs, keratino-
cytes, and BrEpCs, whereas apoptotic HeLa and CaCo-2
cells were generated by UVB irradiation. To exclude that
a different method of apoptosis was the reason for differ-
ent expression of PDC-E2, staining with mAb against
PDC-E2 using UVB-irradiated HIBECs was performed
and the same results were observed.
PDC-E2 Is Not Altered in Apoptotic HIBECs and
Localizes Within Blebs. The localization of PDC-E2
was studied in apoptotic HIBECs by indirect immuno-
ﬂuorescence and compared with other human cell lines.
Apoptotic cells were identiﬁed by morphological criteria;
DAPI staining was preferred over the use of terminal de-
oxynucleotidyl transferase–mediated dUTP nick-end la-
beling (TUNEL) to detect apoptotic cells because of its
greater speciﬁcity, since TUNEL identiﬁes fragmented
DNA in both apoptotic and necrotic cells and hence may
overestimate the number of apoptotic cells. First, HI-
BECs were stained with sera from patients with PBC (n
20) before and after induction of apoptosis, using both
IgG and IgA AMA isotypes. As expected, nonapoptotic
cells presented the typical punctuate cytoplasmic mito-
chondrial immunoﬂuorescence pattern (Fig. 2A), nega-
tive staining for annexin-V, and normal nuclear
morphology. After staining was performed under the
same conditions following induction of apoptosis with 1
mM GCDC in the absence of serum and growth factors,
apoptotic HIBECs expressed positive PDC-E2 staining
that could be localized with annexin V within apoptotic
blebs and fragments (Fig. 2B). No detectable staining was
Fig. 1. Human intrahepatic biliary epithelial cells (HIBECs) and four other cell types were cultured in normal media (NM) or serum-free media (SFM)
under optimal conditions to induce apoptosis, either by exposure to bile salts (GCDC) or ultraviolet B (UVB) irradiation (see Patients and Methods).
(A) Induction of apoptosis was investigated by ﬂow cytometry after double staining with FITC-labeled annexin V and propidium iodide. The use of 1
mM GCDC in the absence of serum, or growth factors, induced apoptosis in 39% of HIBECs, 49% of BrEpCs, and 51.7% of keratinocytes, whereas
no signiﬁcant apoptotic response was observed in transformed cell lines. UVB irradiation induced apoptosis in just 11% of HIBECs and a higher level
of double positive propidium iodide/annexinV cells, most probably referable to necrotic cells. (B) Different concentrations of GCDC in NM or SFM
were tested to establish proapoptotic concentrations for HIBECs, with 1 mM proving optimal. (C) HIBECs after exposure to GCDC 1 mM in SFM were
assessed by confocal microscopy, revealing typical apoptotic morphology with blebbing of the membrane (*), nucleolar degeneration (short arrow),
and apoptotic fragments (long arrow). A 100 oil-immersion objective was used.
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noted on cells treated with either the secondary antibody
alone or with normal mouse IgG instead of the mAb (data
not shown). These ﬁndings were also reproduced in HI-
BECs following UVB irradition and incubated in fresh
media at 37°C for 6 hours (data not shown).
Immunoﬂuorescence with murine mAb conﬁrmed the
results obtained with the human sera, and apoptotic HI-
BECs retained the PDC-E2–speciﬁc staining within the
apoptotic blebs. There were no differences in staining
using each of the AMA-positive sera from the patients
with PBC according to age, disease stage, or therapy with
ursodeoxycholic acid, and the staining patterns were sim-
ilar to those obtained with the AMA-IgA (Fig. 2C,D).
Preincubation overnight with human recombinant
PDC-E2 completely removed the capacity of the sera to
stain normal and apoptotic cells (Fig. 2). Serum samples
from patients with AMA-negative PBC (n  10), AIH
(n  5), SLE (n  5), PSC (n  5), CHC (n  5), and
healthy controls (n 10) failed to produce any staining of
HIBECs (Table 1).
Localization of PDC-E2 Within Apoptotic Blebs Is
Speciﬁc for HIBECs. PDC-E2 localization was investi-
gated using the clone 2H-4C8 mAb and sera from pa-
tients with PBC and controls using a variety of different
human cell lines (Table 1, Fig. 3). All experiments were
performed before and after induction of apoptosis under
the same conditions as speciﬁed above for HIBECs. Be-
fore apoptosis induction, each of the cell lines manifested
the typical cytoplasmic staining of mitochondria when
the clone 2H-4C8 mAb was used (Fig. 3, upper row).
Following apoptosis induction, none of the control cell
lines had PDC-E2 staining (Fig. 3, lower row). None of
the cell lines used demonstrated detectable cytoplasmic
staining when sera from patients with AMA-negative
PBC, AIH, SLE, PSC, CHC, or healthy controls were
used (data not shown).
These morphological observations were corroborated
by western blot analysis wherein PDC-E2 was readily de-
Fig. 2. Staining of nonapoptotic or apoptotic HIBECs using an AMA-positive PBC serum (A,B), serum from a patient with PBC with monoclonal
production of IgA-AMA (C,D), and using the same AMA-positive serum after absorbtion with recombinant PDC-E2 (E,F). The immunoﬂuorescence
staining was performed with three ﬂuorochromes: Cy3-conjugated secondary antibody (red, yellow-orange when costained with green), FITC-labeled
annexin-V (green), and DAPI (blue) for apoptosis detection. Apoptotic cells (*) were identiﬁed by morphological criteria: high nuclear density,
chromatin condensation and nuclear fragmentation revealed with DAPI (blue), and characteristic blebbing of the cell membrane revealed with
annexin-V (green). Positive staining of blebs and apoptotic fragments (arrows) was observed using unabsorbed PBC sera and was virtually absent
after absorption. Apoptosis was conﬁrmed in all experiments (*). Scale bar represents 20 m.
Table 1. Prevalence of staining for PDC-E2 in blebs of
various cell types undergoing apoptosis using PBC and
control sera. Of note, speciﬁc bleb staining was observed in
virtually all HIBEC when AMA-positive PBC sera were used.
This staining was not observed in non-apoptotic cells.
Fisher’s Exact Test was used to calculate statistical
signiﬁcance between HIBEC and the other cell types.
HIBEC Control cells*
PBC AMA ve 20/20 0/40**
PBC AMA -ve 0/10 0/20
Control sera*** 0/30 0/60
* Control cells include in equal distribution, transformed cells (HeLa and
CaCo-2 cells) and non-transformed human epithelial cells (keratinocytes and
bronchial epithelial cells).
** p value  0.0001 compared to HIBEC
*** One third of the control sera were from healthy subjects, and two thirds
were from patients with systemic lupus erythematosus, autoimmune hepatitis,
primary sclerosing cholangitis or chronic hepatitis C.
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tected in lysates of isolated apoptotic bodies obtained
fromHIBECs, whereas no such reactivity was observed in
lysates from HeLa cells and BrEpCs (Fig. 4).
PDC-E2 in Apoptotic Blebs Is Accessible to Anti-
body Recognition. AMA staining in normal cells re-
quires the use of a perforating agent due to the
conservation of membrane integrity, but we hypothesize
that during apoptosis the mitochondrial antigen became
accessible to the immune system. To determine whether
the permeabilization agents were responsible for the ac-
cess of autoantibodies to PDC-E2 within blebs, we
stained HIBECs with the clone 2H-4C8 mAb in the ab-
sence of Triton X-100. Results obtained showed that
while the absence of Triton X-100 did not modify the
positive staining of blebs in apoptotic HIBECs (Fig. 5),
no differences were observed in the other cell lines because
all of them lose AMA staining during apoptosis. These
results were obtained with 12 of 20 AMA-positive PBC
samples whereas sera from patients with AMA-negative
PBC (n  5), AIH (n  5), SLE (n  5), PSC (n  5),
CHC (n  5), or healthy controls (n  5), or the use of
secondary antibody alone failed to demonstrate any stain-
ing (Table 3).
Discussion
Wedemonstrate in this report that PDC-E2, themajor
AMA autoantigen, is detectable in its antigenically reac-
tive form within apoptotic blebs, speciﬁcally in cultured
human BECs and not in other cell types, thus providing
one explanation for the organ-speciﬁc pathology noted in
human PBC. We thus suggest that the unique character-
istics of BECs during apoptosis might constitute the
pathogenic link between the ubiquitous distribution and
high degree of conservation across species of the AMA
autoantigen and the organ speciﬁcity of PBC pathology.
It has been previously reported that PDC-E2 remains
intact and retains its immunogenicity during BEC apo-
ptosis due to a cell lineage–speciﬁc lack of glutathiola-
tion.13,29 This “apoptotic exposure” of PDC-E2 appears
to be limited to BECs, and itmay ultimately have a critical
pathogenic relevance to both inductive and effector stages
of PBC. The formation of apoptotic bodies and fragments
is essential during apoptosis to limit the escape of intra-
cellular content and preclude any ensuing immunological
responses against intracellular autoantigens with inﬂam-
matory reactions.30,31 Nevertheless, apoptotic blebs and
Table 2. Number of apoptotic cells in which blebs contain
PDC-E2. The apoptotic cells were stained as described with
sera from PBC AMA positive patients (n20). Values are
expressed as mean  SD. Apoptotic index was derived from
DAPI-apoptotic nuclei/total nuclei x 100. An individual
apoptotic cell was considered positive when PDC-E2 staining
was observed in at least one of its blebs. Student’s t-test
was used to calculate p values.
Cell type
Apoptotic
index
Cells with positive staining
for PDC-E2 within blebs
HIBEC 38 2.2 88 0.7
Keratinocytes 51 0.7 0 1.3*
BrEpC 48 1.7 0 0.4*
HeLa 42 1.2 0 0.7*
CaCO-2 61 3.5 0 0.3*
* p value  0.0001 compared to HIBEC
Fig. 3. Apoptosis-dependent anti-PDC-E2 staining in various human cell types, with nonapoptotic cells shown in the upper row and apoptotic cells
in the lower row. Immunoﬂuorescence staining was performed with three ﬂuorochromes: mAb against PDC-E2 and Cy3-conjugated secondary antibody
(red, yellow-orange when costained with green); FITC-labeled annexin-V (green); and DAPI (blue) for apoptosis detection. Apoptotic cells (*) were
identiﬁed as described in Fig. 2. Nonapoptotic cells (upper row) have a normal AMA pattern of immunoﬂuorescence staining (red). Apoptotic cells
(lower row) show differences between HIBECs that retained mitochondrial staining within blebs and fragments (arrow) after apoptosis, and other cell
types (CACO-2 cells, HeLa cells, human keratinocytes, and human bronchial epithelial cells) that lost mitochondrial staining after apoptosis. A 100
oil-immersion objective was used. Scale bar represents 20 m.
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fragments can under some circumstances constitute a ma-
jor source of immunogens in autoimmune diseases that
involve the targeting of ubiquitous autoantigens.32 Thus,
dysregulation of apoptosis or the ineffective removal of
apoptotic cells has been documented in patients with
SLE4,7,33 and the development of antibody-mediated
myocarditis of infants born tomothers with anti-SSA/Ro-
SSB/La.7 Also, Kupffer cell engulfment of apoptotic bod-
ies from hepatocytes promotes inﬂammation and
ﬁbrogenesis.34,35
Our observations may help seal several remaining gaps
in the understanding of induction and perpetuation of
PBC, albeit raising new questions. First, intact PDC-E2
in apoptotic fragments from BECs could be taken up by
intrahepatic dendritic cells and transferred to regional
lymph nodes for priming of cognate T cells, thus initiat-
ing PBC, but this attractive scenario still requires an ex-
planation for the primum movens in the ﬁrst place for
apoptosis and this is likely not PBC-speciﬁc. Second, the
accessibility of PDC-E2 within apoptotic blebs to auto-
antibodies appears to support the pathogenic role of AMA
as well as T cells in the perpetuation of BEC injury, even
though antibody titers do not correlate with the clinical
features or stages of PBC, and AMA-negative patients are
clinically indistinguishable from their AMA-positive
counterparts.36 Nevertheless, the appearance of serum
AMAdoes often herald disease onset sometimes by several
years.16 Third, we can propose that PDC-E2 within apo-
ptotic blebs will also be recognized by major histocom-
patibility complex class I–restricted CD8 T cells; this
point helps explain the BEC pathology in AMA-negative
PBC. Interestingly, our lab has recently demonstrated the
presence of autoreactive T cells to PDC-E2 in patients
with AMA-negative PBC.37 These data are also of partic-
ular relevance in view of the major pathogenic role of
these cells in producing PBC-like liver lesions in animal
models.38 Fourth, our ﬁndings are consistent with the
likelihood that PBC cholangiocytes do not manifest any
unique features that make them the target of autoimmu-
nity,37 noting the frequent recurrence of PBC following
allogeneic liver transplantation.14 The latter two issues
may ultimately be combined with the fact that the donor
and recipient major histocompatibility complex class I
alleles are major determinants of the allograft outcome.39
Fig. 4. Western blots show that PDC-E2 is localized unmodiﬁed within apoptotic bodies (AB) from HIBECs but not from other cell lineages. ABs
were isolated by ﬁltration and ultracentrifugation after induction of apoptosis (see Patients and Methods). PDC-E2 was detected by western blot in
lysates obtained from nonapoptotic cells and ABs using (1) mAb against PDC-E2, (2) AMA-positive serum, (3) AMA-IgA isotype, (4) mAb against
caspase-3, and (5) serum from a healthy control. PDC-E2 was detected in ABs from HIBECs when tested with mAb and with PBC sera of two different
Ig isotypes. ABs from HeLa cells and BrEpCs did not show the presence of PDC-E2 whereas, as expected, lysates from nonapoptotic cells did so.
The 18-kDa subunit of caspase-3 generated during apoptosis is localized within apoptotic blebs, and hence exposure to mAb to caspase-3 was used
to validate formation of blebs.
Fig. 5. Staining of nonapoptotic (upper row) and apoptotic (lower
row) HIBECs in the absence or presence of a membrane-permeabilizing
agent, Triton X-100. AMA staining in normal cells requires pemeabiliza-
tion of the cell (A); lacking this, no staining is observed due to retention
of membrane integrity (C); apoptotic HIBECs (*) stained with a mAb
against PDC-E2, with positive staining demonstrable within the blebs
(arrow) (B); apoptotic HIBECs retained the bleb staining even without
permeabilization (D). No staining was observed with serum from patients
with AMA-negative PBC, PSC, AIH, SLE, CHC, or healthy subjects (not
shown). Scale bar represents 20 m.
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Fifth and ultimately, the ensuing B andT cell autoreactive
response may account for the perpetuation of the im-
mune-mediated damage to BECs with a major role also
played by elements of innate immunity which appears to
be enhanced in PBC.40,41
Our data imply that the postapoptotic release of intact
mitochondrial autoepitopes in small bile ducts is one con-
tributor to this speciﬁcity. Indeed, we should note that, as
previously reported, the overexpression of Bcl-2 (B cell
lymphoma-2), speciﬁcally in apoptotic small BECs, in-
hibits PDC-E2 glutathiolation and prevents the loss of
antigenicity.13,42 However, other factors have also been
incriminated in playing a role in the selective destruction
of small BECs. In particular, there are dramatic differ-
ences in expression of trefoils in small versus large bile
ducts, suggesting not only an imbalance of homeostasis,
but also a differential ability to repair or restitute cell
damage.43
Our data also demonstrate that we are able to detect
PDC-E2 without cell permeabilization. There are three
explanations for this observation. First, PDC-E2may leak
out to the cell surface and is thus being detected on the cell
membrane. Second, the cells undergoing apoptosis have
holes in their cell membrane created by cellular proteases
which allow passage into and localization of immuno-
globulin in the bleb. Third, there may be a role for frag-
ment crystallizable receptor–mediated uptake in the
apoptotic cell. Future experiments will address these pos-
sibilities.
In conclusion, the evidence provided here leads to new
scenarios in the pathogenesis of PBC and may constitute
a credible link between the several convenient and incon-
venient truths available thus far.37 However, it does not
overcome all of the major challenges in PBC etiology, nor
the need to ascertain the genetic basis of disease suscepti-
bility and environmental triggers for cholangiocyte injury
and apoptosis as an initial step in tolerance breakdown.
Treatments that could modulate apoptosis44 should not
be overlooked, and their assessment is warranted in re-
cently established murine models for PBC.45-47
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